0.4800USD+6.67%Mkt Cap: 23.19M USDP/E: —Last update: 2026-06-01
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The …
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap23.19M USD
Enterprise Value-15.76M USD
Revenue (TTM)—
Gross Profit-41.73M USD
Net Income (TTM)-60.82M USD
Revenue/Share—
Last Price0.4800 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees39
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.45
PEG—
EV/EBITDA0.29
EV/Revenue—
P/S—
P/B1.79
EPS (TTM)-1.21
EPS (Forward)-0.99
52W Range
0.40404% of range2.380
52W High2.380 USD
52W Low0.4040 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-245.20%
ROA-87.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.29M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-15.93%
Net Debt-37.63M USD
Net Debt/EBITDA0.69
Balance Sheet
Debt/Equity1.52
Current Ratio1.26
Quick Ratio1.21
Book Value/Sh0.2510 USD
Cash/Share0.9560 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)4.000 USD
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.48.60M
Float41.23M
Insiders5.61%
Institutions35.21%
Short Interest
Short Ratio1.4d
Short % Float1.66%
Short % Out.1.37%
Shares Short667.63K
Short (prev mo.)787.45K
Technical
SMA 500.7499 (-36.0%)
SMA 2001.005 (-52.2%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)541.44K
Avg Vol (10d)649.83K
Technical Indicators
RSI (14)31.9
MACD-0.0886
MACD Signal-0.0880
MACD Hist.-0.0006
BB Upper0.7605 USD
BB Middle0.5525 USD
BB Lower0.3446 USD
BB Width75.26%
ATR (14)0.0637 USD
Vol Ratio (20d)0.35x